Cost-saving Implications of Correct Antibiotic Use

By Staff Writer

March 25, 2024

Introduction:

In an era where antibiotic resistance is a growing global concern, understanding correct antibiotic use is crucial. It not only ensures effective treatment but also paves the way for significant cost savings. By exploring the recent updates from the World Health Organisation (WHO) and the National Institute for Health and Care Excellence (NICE), we can glean valuable insights into the cost-saving implications of proper antibiotic use.

The WHO’s Data Visualisation Dashboard

In 2015, the WHO launched a global action plan on antimicrobial resistance (AMR) and use (AMU), highlighting the need for robust data to combat AMR effectively. The Global Antimicrobial Resistance and Use Surveillance Systems (GLASS) was born out of this need. GLASS, which now includes data from 127 countries, territories, and areas (CTAs), provides a comprehensive set of AMR and AMU data available on a user-friendly dashboard.

The Power of Data Visualisation

The GLASS dashboard summarises resistance rates for 23 antibiotics across eight bacterial pathogens. It provides insights into the quality assurance and standards of national AMR surveillance systems. By presenting AMR rates for 2020 and 2021 and a time series of AMR rates, it allows for informed interpretation of global estimates. Further, it presents a comprehensive list of the antibacterials that constitute 75% of the overall national antibacterial consumption. Countries enrolling and reporting antimicrobial use data to GLASS have increased over time, and WHO works with governments to expand. Improvements to data quality and user experience are ongoing. WHO should release a handbook on using AMU surveillance data for policy and practice by 2024.

Updated NICE Guidance on Antibiotics

Meanwhile, NICE has recommended better targeting of antibiotics for suspected sepsis. The guideline aims for improved precision in the administration of antibiotics for suspected sepsis to guarantee prompt treatment for the appropriate individuals, while avoiding excessive usage that may contribute to antibiotic resistance. The updated guidance utilises the National Early Warning Score (NEWS2) to assess patients with suspected sepsis, ensuring that those most severely ill receive broad-spectrum antibiotics within an hour. The NICE guidance advises the utilisation of NEWS2 for evaluating individuals aged 16 or older, who are not currently pregnant, and are in an acute hospital, acute mental health facility, or ambulance, in order to investigate suspected cases of sepsis.

The Cost-saving Potential of Targeted Antibiotic Use

The annual number of diagnosed sepsis cases in the UK is at least 245,000. In 2017, the UK Sepsis Trust conducted a data study which revealed that there were 200,000 hospital admissions in England where sepsis was diagnosed. The updated guidance is expected to reduce the risk of antibiotic resistance. More importantly, to give healthcare professionals more time to investigate less severely ill patients. This more targeted approach to antibiotic use not only ensures the right treatment but also has significant cost-saving implications.

Conclusion:

In conclusion, the correct use of antibiotics, informed by robust data and targeted guidelines, holds the promise of significant cost savings. As we continue to grapple with the global challenge of antibiotic resistance, these insights offer a beacon of hope.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.